CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
AstraZeneca
Essen Biotech
Genentech, Inc.
Memorial Sloan Kettering Cancer Center
VM Oncology, LLC
University of Pittsburgh
Merus B.V.
Essen Biotech